Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MedImmune -- Ignore unavailable to you. Want to Upgrade?

To: James Mortensen who wrote (124)	6/25/1998 6:21:00 PM
From: JS Ogrady	Read Replies (2) \| Respond to of 416

I am a new investor in MediImmune. I am also a pediatrician. I can't emphasize strongly enough that Medi's new passive immunization for RSV is a HUGE development in the field of pediatrics and pediatric/neonatal critical care. A large pre- centage of pediatric intensive care costs during the fall and winter are associated with RSV related sequelae. If this new vaccine is as effective as indicated by company product infor- mation I am quite sure the indications will be expanded to other at-risk groups. Ross Labaratory sales reps were called and notified the day of the announcement. My conversations with these detailers indicate Ross thinks this drug may be bigger than their current top sales drug- Survanta. And I have to agree. Currently only neonates who have to be intubated receive Survanta, while Synergis will probably be given to every premature infant under 34 weeks who has RDS( a far greater number than those who end up entubated and on ventillators.) Regardless, the pediatric community is very excited and I think the only thing holding this stock below 80 is that the drug approval was announced in the summer. Once RSV season is in full tilt, media coverage of Synergis will be intense.